Cemiplimab-rwlc is available in a liquid form which should be given only by a healthcare provider as an intravenous infusion directly into the vein very slowly for at least 30 minutes.
The required amount of cemiplimab-rwlc to be injected should be diluted with 0.9% sodium chloride or 5 % dextrose solution and mixed by gentle inversion.
The vial and the diluted solution of cemiplimab-rwlc should be visually checked for any visible particles or coloration before injecting. The contents should be disposed of if such discoloration or changes occur.
The dose of cemiplimab-rwlc can either be reduced or the treatment can be permanently discontinued based on the severity of the side effects.
The treatment with cemiplimab-rwlc can be continued until the patient shows any progression of the disease or till the treatment with cemiplimab-rwlc does not result in intolerable toxicity.
• If there is an allergy to cemiplimab-rwlc
• Pregnant and breastfeeding women
• Children
The required amount of cemiplimab-rwlc to be injected should be diluted with 0.9% sodium chloride or 5 % dextrose solution and mixed by gentle inversion.
The vial and the diluted solution of cemiplimab-rwlc should be visually checked for any visible particles or coloration before injecting. The contents should be disposed of if such discoloration or changes occur.
Dosage & When it is to be taken
The recommended adult dose of cemiplimab-rwlc is 350 mg for every three weeks.The dose of cemiplimab-rwlc can either be reduced or the treatment can be permanently discontinued based on the severity of the side effects.
The treatment with cemiplimab-rwlc can be continued until the patient shows any progression of the disease or till the treatment with cemiplimab-rwlc does not result in intolerable toxicity.
When it is not to be taken (Contraindications)
Cemiplimab-rwlc should not be used in patients-• If there is an allergy to cemiplimab-rwlc
• Pregnant and breastfeeding women
• Children
